{
  "ticker": "ACW",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02963406",
  "id": "02963406",
  "pages": 3,
  "price_sensitive": true,
  "date": "20250630",
  "time": "0911",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250630/pdf/06l7pbwl6765w4.pdf",
  "summary": "### Material Information Summary:  \n\n- **Non-dilutive R&D Funding Secured**:  \n  - **Initial tranche**: $3.0m received (secured against FY25 R&D Tax Incentive (RDTI)).  \n  - **Further conditional funding**: Up to $10.8m ($2.9m for FY25 RDTI, $7.9m for FY26 RDTI), pending due diligence.  \n  - **Total potential funding**: Up to $13.8m.  \n\n- **Use of Funds**:  \n  - Accelerate XanaMIA phase 2b/3 Alzheimer\u2019s trial (35 sites open in Australia/US).  \n  - General working capital.  \n\n- **Cash Position**:  \n  - **Pro forma cash balance**: ~$16.4m (includes $3.0m initial tranche + $13.4m existing cash).  \n  - **Cash runway**: Extended to mid-2026.  \n\n- **Loan Terms**:  \n  - Repayment due upon receipt of RDTI rebate (expected late 2025).  \n  - Commercial interest rate; early repayment permitted after 90 days.  \n\n*(No material information omitted; summary excludes operational/clinical details unrelated to capital/funding impact.)*",
  "usage": {
    "prompt_tokens": 2457,
    "completion_tokens": 265,
    "total_tokens": 2722,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-29T23:15:35.311186"
}